Small molecule · Inhibitor of gamma secretase complex and Notch receptor (NOTCH1) · developed by Immunome
Varegacestat is an orally bioavailable gamma secretase and pan-Notch inhibitor. It binds gamma secretase and blocks cleavage and release of the Notch intracellular domain, preventing Notch-regulated gene expression. It is being studied in desmoid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04871282 | Phase 2/3 | Desmoid | Active not recruiting | IMNM |
| NCT07610005 | Phase 1 | Healthy | Recruiting | IMNM |
| NCT06841315 | Phase 1 | Healthy Volunteer | Completed | IMNM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
DesmoidDesmoid TumorHealthyHealthy VolunteerHepatic Impairment (HI)
Updated Oct 18, 2026. Something wrong or missing? Report it on the IMNM page.
See IMNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMNM catalysts and pipeline →